Vident Investment Advisory’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Vident Investment Advisory’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-22,951	Closed	-$858K	–	984
2018 Q1	$858K	Buy	22,951 +6,224	+37%	+$441K	0.03%	420
2017 Q4	$1.22M	Buy	+16,727	New	+$1.38M	0.06%	348
2017 Q2	–	Sell	-8,961	Closed	-$1.94M	–	455
2017 Q1	$1.94M	Buy	8,961 +1,493	+20%	+$213K	0.19%	260
2016 Q4	$691K	Buy	7,468 +415	+6%	+$46.8K	0.08%	317
2016 Q3	$953K	Buy	7,053 +48	+0.7%	+$4.77K	0.13%	299
2016 Q2	$710K	Buy	7,005 +2,617	+60%	+$324K	0.1%	314
2016 Q1	$718	Buy	4,388 +2,048	+88%	+$415K	0.04%	361
2015 Q4	$766K	Buy	2,340 +1,660	+244%	+$540K	0.1%	340
2015 Q3	$219K	Buy	+680	New	+$299K	0.03%	720

Other funds holding LUMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vident Investment Advisory's LUMO Position: Q2 2018 in Review

Vident Investment Advisory sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2018, closing a stake of 22,951 shares — an estimated $858K sold.

Vident Investment Advisory first reported a position in LUMO in Q3 2015 and held it in 9 quarters. The position peaked at $1.94M in Q1 2017. 106 funds tracked by Wall St. Rank hold LUMO as of Q2 2018.

Vident Investment Advisory reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Vident Investment Advisory sold 22,951 Lumos Pharma, Inc. Common Stock shares in Q2 2018, an estimated $858K.
Vident Investment Advisory first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2015 and held it in 9 quarters.
Vident Investment Advisory's Lumos Pharma, Inc. Common Stock position peaked at $1.94M in Q1 2017.
106 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2018.

Based on Vident Investment Advisory's 13F filing for Q2 2018, filed 14 Aug 2018.